Recent Analysts’ Ratings Updates for Certara (CERT)

A number of research firms have changed their ratings and price targets for Certara (NASDAQ: CERT):

• 11/9/2026 – Certara was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 11/6/2026 – Certara had its “hold” rating reaffirmed by Jefferies Financial Group. They now have a $12.00 price target on the stock.
• 11/6/2026 – Certara had its “neutral” rating reaffirmed by UBS Group. They now have a $13.00 price target on the stock.
• 11/6/2026 – Certara had its price target raised by Barclays from $9.00 to $12.00. They now have an “equal weight” rating on the stock.
• 10/16/2026 – Certara had its price target raised by KeyCorp from $9.00 to $12.00. They now have an “overweight” rating on the stock.
• 10/13/2026 – Certara had its price target raised by TD Cowen from $9.00 to $11.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Certara was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 10/7/2026 – Certara had its price target raised by Barclays from $7.50 to $9.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Certara was downgraded by UBS Group from “buy” to “neutral”. They now have a $10.00 price target on the stock.

Certara Trading Down 0.7%

CERT traded down $0.09 during mid-day trading on Tuesday, reaching $12.13. The stock had a trading volume of 2,879,894 shares, compared to its average volume of 2,585,002. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.58 and a current ratio of 2.58. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $12.61. The stock has a market capitalization of $1.85 billion, a P/E ratio of -28.88 and a beta of 1.30. The firm’s fifty day simple moving average is $9.41 and its two-hundred day simple moving average is $7.36.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. Certara had a positive return on equity of 3.36% and a negative net margin of 16.14%. The firm had revenue of $94.90 million during the quarter, compared to analyst estimates of $92.01 million. During the same period last year, the company earned $0.14 earnings per share. The company’s revenue was down 9.3% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. On average, equities analysts predict that Certara, Inc. will post 0.21 EPS for the current year.

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.